Photo Gallery: Prime Minister Carney Visits BC
Prime Minister Mark Carney continued his visit to British Columbia on Monday as he toured the Canadian Forces Maritime Experimental and Test Ranges facility on Vancouver Island. Wearing a navy blue suit, Carney visited the facility near Nanoose Bay, about 30 kilometres north of Nanaimo, for about 2 1/2 hours, during which he toured the Royal Canadian Navy vessel Sikanni. On Sunday, Carney met with Eby as well as officials from the Vancouver Fraser Port Authority. Carney and Eby discussed U.S. tariffs and a renewed animosity in the long-running softwood lumber dispute. After the meetings, Carney made a surprise appearance at Vancouver's Pride Parade, marching for about a kilometre along the route beginning outside B.C. Place Stadium. Here's a look at the Prime Minister's tour over the last two days. This report by The Canadian Press was first published Aug. 4, 2025.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
Recombinant Human Hair Keratin Protein Market 2025 Trends and Updates
The global recombinant human hair keratin protein market is growing quickly as more people seek effective hair health solutions and advanced wound healing treatments, says a study published by Towards Healthcare a sister firm of Precedence Research. Ottawa, Aug. 14, 2025 (GLOBE NEWSWIRE) -- The global recombinant human hair keratin protein market is on a strong growth trajectory, with revenues expected to climb into the hundreds of millions by 2034. This momentum is being fueled by a rising focus on hair health, a noticeable increase in bleeding disorder cases, and a wave of fresh investments pouring into biotechnology. Together, these factors are creating fertile ground for innovation and demand across multiple industries. Companies in North America, Asia-Pacific, and Europe are actively investing in research, driving innovations, and forming partnerships to open new market opportunities. The Complete Study is Now Available for Immediate Access | Download the Sample Pages of this Report @ Key Takeaways North America dominated the recombinant human hair keratin protein market in 2024. Asia Pacific is estimated to grow at the fastest CAGR during the forecast period. Market Overview & Potential Recombinant human hair keratin protein is a lab-engineered protein that replicates the structure and function of natural keratin in human hair. It is produced via recombinant DNA technology, resulting in a highly controlled and pure form of keratin that differs from traditional extracts. This makes it a valuable material for applications such as wound healing and hair care. Conventional keratin extraction methods can be inconsistent and may not yield pure products, whereas recombinant production ensures greater purity and enables precise control over the protein's amino acid sequence and structure, resulting in more predictable properties. Top Countries in Recombinant Human Hair Keratin Protein Market: United States Contribution: Leading the global market with strong demand for medical-grade recombinant keratin, supported by a robust biotech ecosystem and healthcare infrastructure. Strength: Advanced R&D capabilities and regulatory support for therapeutic and regenerative applications. China Contribution: Fastest-growing market, fueled by a rapidly expanding cosmetics and personal care sector. Strength: Strong domestic production capabilities, rising consumer awareness, and increasing investment in biotech innovations. Germany Contribution: Key contributor in Europe, especially in high-purity recombinant keratin for medical and cosmetic formulations. Strength: Expertise in biotechnology and demand for premium, high-performance personal care products. France Contribution: Strong market for cosmetic applications, particularly in haircare and skincare products incorporating natural bioactive ingredients. Strength: Sophisticated beauty industry and preference for sustainable, biologically derived ingredients. India Contribution: Emerging player in both medical and cosmetic applications of recombinant keratin. Strength: Large population base, rising demand for advanced hair and skin treatments, and growing domestic manufacturing activity. You can place an order or ask any questions, please feel free to contact us at sales@ What is the Growth Potential Responsible for The Growth of The Recombinant Human Hair Keratin Protein Market? The growth of the market is driven by the growing application in the biomedical field due to its biocompatibility, ability to promote cell growth, and biodegradability, which makes it ideal for various medical uses, driving the growth. The key applications, like tissue regeneration, drug delivery systems, and wound healing, are supporting the growth of the market. Other key drivers are biotechnology research due to the growing biotechnology sector, in personal care and cosmetics, and sustainable and ethical sourcing. Increasing incidence of chronic diseases, and government initiatives in R&D in life sciences research and development. What Are the Growing Trends Associated with the Recombinant Human Hair Keratin Protein Market? The technological advancements like innovation in synthetic biology and demonstration technology for the development of new and tailored properties, and more efficient production methods. Rising demand in the cosmetic sector for the development of hair care products for improving the shine, strengthening the damaged hair, and reducing the frizz increases the demand for the product. The growing biomedical applications, like in wound healing, tissue engineering, and drug delivery, fuel the demand for the product, supporting the growth. Shift towards sustainable and ethical products, like growing demand and interest in vegan and plant-based keratins, improves the market growth of the market. Increasing awareness and adoption due to the benefits offered and availability of the products make it a preferred choice, and increase the growth. What Is the Growing Challenge in the Recombinant Human Hair Keratin Protein Market? However, the recombinant human hair keratin protein market faces challenges including production issues, consistency concerns, and consumer perceptions. Although recombinant technology provides advantages like higher purity and specific amino acid composition, it also risks problems like misfolding, aggregation, and low yields. Additionally, high production costs, especially due to specialized equipment and chemicals, can hinder market growth. Consumer preferences for natural or plant-based products, along with safety and efficacy concerns regarding keratin treatments, could also limit market expansion. Get the latest insights on life science industry segmentation with our Annual Membership: Regional Analysis How Did North America Dominate the Recombinant Human Hair Keratin Protein Market in 2024? North America led the recombinant human hair keratin protein market in 2023. Growth is driven by increased investments, collaborations, key industry players, and advanced R&D activities. The US and Canada are the primary markets, with companies like Novus Biologicals, Abcam Ltd., PROGEN, and OriGene contributing significantly. US government initiatives to promote biotech research further boost the market, complemented by over 130 recombinant proteins approved by the US FDA for clinical use. In the UK, industries are exploring innovative methods to enhance hair growth, quality, and reduce hair fall using recombinant human hair keratin protein. Additionally, rising awareness about hair health is fueling demand for these products. What Made Asia Pacific Significantly Grow in The Recombinant Human Hair Keratin Protein Market in 2024? Asia-Pacific is expected to grow the fastest in the recombinant human hair keratin protein market during the forecast period. Market growth is driven by increasing research and development activities, rising government funding, a growing number of bleeding disorder cases, favorable infrastructure, and lower costs. Recombinant keratin has been shown to promote skin wound healing and improve blood clotting. In China, about 65,000 people suffer from hemophilia, while India has the second-largest number of hemophilia cases worldwide, with 136,000 patients. The demand for products that support hair growth and reduce hair loss is rapidly increasing in China, South Korea, and Japan. Companies like Tsubaki use recombinant human keratin to develop luxurious hair treatments that attract beauty-conscious consumers. Become a valued research partner with us - Recent Developments In July 2024, Yuhan Corp, a South Korean pharmaceutical company, signed a comprehensive R&D collaboration agreement with ProGen. The collaboration was made to strengthen next-generation biologics and drug development research. In April 2024, Bio-Techne Corporation announced a strategic distribution agreement with Thermo Fisher Scientific. The agreement will distribute Bio-Techne's innovative products, such as antibodies, proteins, immunoassay kits, reagents, and enzymes, to laboratories and research institutions across Europe. Browse More Insights of Towards Healthcare: The global GMP grade cytokines market is valued at USD 2.54 billion in 2024, expected to rise to USD 2.79 billion in 2025, and anticipated to reach approximately USD 6.48 billion by 2034. This represents a steady growth trajectory at a CAGR of 9.84% from 2025 to 2034. The global recombinant proteins market is estimated at USD 3.36 billion in 2025 and is forecasted to climb to around USD 8.08 billion by 2034, expanding at a CAGR of 10.24% over the forecast period. The recombinant lysyl endopeptidase market was valued at USD 38 million in 2023 and is projected to reach USD 67.06 million by 2034, growing at a CAGR of 5.3% between 2024 and 2034. The global hair transplant market stands at USD 7.33 billion in 2024, rising to USD 8.87 billion in 2025, with projections indicating a surge to nearly USD 49.44 billion by 2034—signaling rapid expansion. The hair treatment drug market was worth USD 1.4 billion in 2023 and is anticipated to grow to USD 2.99 billion by 2034, recording a CAGR of 7.14% during 2024–2034. The global host cell protein testing market is valued at USD 2.37 billion in 2024, estimated to increase to USD 2.56 billion in 2025, and forecasted to hit USD 5.19 billion by 2034, with an expected CAGR of 8.17% from 2025 to 2034. The global protein expression technology market is pegged at USD 2.85 billion in 2024, projected to rise to USD 3.05 billion in 2025, and likely to reach USD 5.58 billion by 2034, reflecting a CAGR of 6.94% over the forecast timeline. The global proteinase K market is valued at USD 4.82 billion in 2024, forecasted to grow to USD 5.23 billion in 2025, and set to reach USD 10.93 billion by 2034, advancing at a CAGR of 8.54% between 2025 and 2034. The global cell-free protein expression market is valued at USD 315.03 million in 2024, expected to grow to USD 342.25 million in 2025, and projected to hit USD 716.26 million by 2034, expanding at a CAGR of 8.63% from 2025 to 2034. The global protein therapeutics market is calculated at USD 375.3 billion in 2024, projected to grow to USD 401.89 billion in 2025, and expected to reach USD 740.07 billion by 2034, advancing at a CAGR of 7.08% over the forecast period. Recombinant Human Hair Keratin Protein Market Key Players Abcam Limited Abbexa, Ltd. Bon Opus Biosciences Creative Diagnostics MyBioSource, Inc. Novus Biologicals OriGene PROGEN ProSpec Wuhan Huamei Biotech Co., Ltd. Regions Covered North America U.S. Canada Asia Pacific China Japan India South Korea Thailand Europe Germany UK France Italy Spain Sweden Denmark Norway Latin America Brazil Mexico Argentina Middle East and Africa (MEA) South Africa UAE Saudi Arabia Kuwait Access our exclusive, data-rich dashboard dedicated to the healthcare market - built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway. Access the Dashboard: Immediate Delivery Available | Buy This Premium Research @ About Us Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research. Dedicated to advancing innovation in the life sciences sector, we build strategic partnerships that generate actionable insights and transformative breakthroughs. As a global strategy consulting firm, we empower life science leaders to gain a competitive edge, drive research excellence, and accelerate sustainable growth. You can place an order or ask any questions, please feel free to contact us at sales@ Europe Region - +44 778 256 0738 North America Region - +1 8044 4193 44 Web: Find us on social platforms: LinkedIn | Twitter | InstagramError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
19 minutes ago
- Yahoo
Rogers Communications selling data centre portfolio to InfraRed Capital Partners
TORONTO — Rogers Communications Inc. has signed a deal to sell its portfolio of nine data centres to InfraRed Capital Partners. Financial terms of the sale were not immediately available. Under the agreement, Rogers will continue to sell data centre services on behalf of InfraRed and will provide network connectivity to the data centres. The deal does not include Rogers corporate data centres used for the company's network and IT purposes. Rogers says the transaction is part of its planned sale of real estate and non-core assets. Net proceeds are expected to be used to repay debt. InfraRed is part of the asset management business of Sun Life. This report by The Canadian Press was first published Aug. 14, 2025. Companies in this story: (TSX:RCI.B, TSX:SLF) The Canadian Press Sign in to access your portfolio
Yahoo
19 minutes ago
- Yahoo
Cohere hires long-time Meta research head Joelle Pineau as its chief AI officer
Investors once saw Canadian AI startup Cohere as a promising contender to challenge OpenAI and Anthropic in the race to build frontier AI models, with its backers pouring roughly $1 billion on their bet on CEO Aidan Gomez, who co-authored a seminal paper on LLMs when he was a 20-year-old Google intern. But Cohere's AI models have fallen behind the state-of-the-art, and its business hasn't scaled like its competitors. Now, the company is bringing in a veteran research leader to revamp its AI efforts: Cohere has hired Joelle Pineau, Meta's former VP of AI research who previously oversaw the tech giant's fundamental AI research (FAIR) lab. In her newly created Chief AI Officer role, Pineau will oversee AI strategy across Cohere's research, product and policy teams. A Canadian AI scientist and McGill Professor, Pineau helped guide the early development of Meta's open Llama AI models alongside Yann LeCun, a pioneer of neural networks. Pineau left Meta in May after nearly eight years with the company. For Cohere this is a big hire, and it is pinning its hopes on the veteran helping it with more research breakthroughs, improving its research and product pipeline, and recruiting top talent. The hire comes at a pivotal moment for Cohere: The company is reportedly seeking to raise up to $500 million at a $6.3 billion valuation — an impressive sum were the startup not competing with the likes of OpenAI, Google, Meta and Anthropic, whose war chests are worth dozens of billions each. But while its rivals are trying to develop AI systems that can match (or exceed) human performance on a wide variety of tasks, Cohere has a narrower focus. The startup primarily builds AI applications that can solve practical problems for enterprises and government agencies, emphasizing privacy and security. In an interview with TechCrunch, Pineau said Cohere's focus on real-world, enterprise applications is something she's excited about. 'A lot of players out there are quite singularly focused on AGI, superintelligence, and so on,' said Pineau, alluding to companies like her former employer, Meta, which recently invested billions in its new Meta Superintelligence Labs (MSL) unit. 'They haven't necessarily figured out what this AI is going to be used for.' She pointed to OpenAI's launch of GPT-5 last week, which many felt was underwhelming, as evidence the timeline to achieving AGI may be 'a little bit longer than we thought.' In the meantime, Pineau says there's a lot of room for more practical AI models to deliver leaps in productivity in different industries. A Canada native, Pineau said she's had her eye on Cohere since they were founded in 2019, and that she's excited to contribute to a company whose founders are based in her home country. Beyond the patriotism, Pineau feels the opportunity with Cohere is a good chance to venture beyond research. At FAIR, Pineau oversaw research teams working on projects that could take anywhere from 18 months to 10 years to deliver. Now, she'll be working within a much tighter timeline, as well as getting involved with customers and products. And even though Cohere has fewer resources than Meta, Pineau said she'll be more agile in her new role. Cohere's latest product is an AI agent platform dubbed North that enterprises and government agencies can deploy privately on their own infrastructure, an attractive notion for many of its customers, which are banks and federal organizations that handle highly sensitive data. That puts Cohere in competition with open-source providers like DeepSeek and Meta, whose models can also be run locally, but at a lower cost. Cohere is betting that by offering more support around its private deployments, it can beat out open models. Pineau said she's particularly interested in gearing more of Cohere's research around North, figuring out ways to develop AI agents in private and secure settings, and creating benchmarks to evaluate these systems. Pineau also said she's interested in exploring how networks of AI agents interact with each other in the real world. One immediate challenge for Pineau will be replacing Cohere's VP of AI Research, Sara Hooker, who announced her departure this week after several years of helping build the company's research program. Hiring an AI researcher of Hooker's caliber may be difficult in the current market given the skyrocketing demand for AI talent. But Pineau sees this as an opportunity to 'bring in a lot of talent,' noting that when she left Meta, several of her former colleagues suggested they'd follow her to a new AI lab. However, she emphasized that Cohere has a solid base of AI researchers, and that it's important to not just bring in anyone. 'Hiring a bunch of superstars doesn't necessarily make a superstar team,' said Pineau. 'It's really about how the people work together.' Of course, Meta's AI units today look very different compared with when Pineau was there just a few months ago. Over the summer, Mark Zuckerberg went on a recruiting spree, reportedly offering some of the industry's best AI researchers compensation packages north of $100 million to join MSL. That prompted OpenAI to also raise compensation for its star employees, thus making it quite difficult for smaller players to land top AI researchers. As Meta, OpenAI and Anthropic throw billions of dollars at their AI efforts, Cohere is trying to do more with less. For Pineau, that will mean making calculated research bets — the kind that can quickly turn into compelling products and keep the company in the race. Sign in to access your portfolio
